Sanofi

Open: 53.91 Close: 53.44 Change: -0.47

The stock market through the eyes of an AI: Sanofi Company Inc.

The game is changing. There is a new strategy to evaluate Sanofi fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Sanofi are: Sanofi, therapy, Flatiron, data, acquisition, care, Pompe, and the …

Concept Map

Semantic Network

Stock Summary

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company also provides cough, cold.

Today's Summary

French drugmaker Sanofi posted better-than-expected earnings for the first quarter. Dupixent sales beat consensus, helped offset declining sales from an established MS pill Aubagio. Analyst Consensus Moderate Buy: $62.00 (15.91% Upside)

Today's News

Flatiron Health embarks on strategic collaboration with sanofi to make clinical trials more efficient by streamlining data acquisition at the point of care. Flatiron Clinical Pipe™ eliminates double data entry, allowing health care providers and research. Sanofi has gambled against gene therapy before, and now it has done so again. Treatments for Pompe already exist in the form of enzyme replacement therapies, and here Sanofi dominates the market. The move for MZE001 looks like a shoring up Sanofis existing franchise. Sanofi achieved a 26% energy reduction in its Cambridge lab space by increasing the temperature from – 80 F to – 70 F. Sanofi Cambridge partners with Seeding Labs to donate reasonably conditioned laboratory tools and equipment to students, scientists and researchers in developing countries. Sanofi ADR Watch list creates SNY Alert SNY US After Hours last Updated: May 1, 2023 5:05 p.m. per Employee $493.47K P/E ratio 15.38 EPS $3.38 Yield 2.58% Dividend $0.30 Ex-Dividend Date. French drugmaker Sanofi posted better-than-expected earnings for the first quarter. Dupixent sales beat consensus, helped offset declining sales from an established MS pill Aubagio. Ovid Therapeutics is tapping into Sam Waksals Cormorant-backed Graviton. Sanofi announced the completion of its acquisit i on of Provention Bio, Inc. The acquisition adds TZIELD (teplizumab-mzwv), an innovative, fully owned, first-in-class therapy in type 1 diabetes to Sanofis core asset portfolio. Sanofi downgraded to Sell from Hold at Deutsche Bank Deutsche Bank downgraded Sanofi to Sell. Analyst Consensus Moderate Buy Average Price Target: $62.00 (15.91% Upside) Sanofi pays a Semiannually dividend of $1.56. Sanofi in-Licenses Pompe Disease Therapy from privately-held Maze Therapeutics for $150M Upfront. Maze has advanced MZE001 through Phase 1 development and recent Financial Times Sanofi/Provention: innovative diabetes drug is a good fit.

Stock Profile

"Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France."

Keywords

Are looking for the most relevant information about Sanofi? Investor spend a lot of time searching for information to make investment decisions in Sanofi. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Sanofi are: Sanofi, therapy, Flatiron, data, acquisition, care, Pompe, and the most common words in the summary are: sanofi, stock, news, market, report, sale, sny, . One of the sentences in the summary was: Dupixent sales beat consensus, helped offset declining sales from an established MS pill Aubagio. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #sanofi #stock #news #market #report #sale #sny.